The characteristics and implication of WHO Essential Medicines Model List 2023
10.3969/j.issn.1674-2982.2024.02.008
- VernacularTitle:2023 年版WHO基本药物示范目录特点分析及启示
- Author:
Yu-Bei HAN
1
,
2
;
Wen-Chen LIU
;
Chen CHEN
;
Cai-Jun YANG
;
Yu FANG
Author Information
1. 西安交通大学药学院 陕西西安 710061
2. 西安交通大学药品安全与政策研究中心 陕西西安 710061
- Keywords:
World Health Organization;
Essential medicines model list;
Selection procedure;
Evidence-based reference;
Medical insurance drug reimbursement list
- From:
Chinese Journal of Health Policy
2024;17(2):53-58
- CountryChina
- Language:Chinese
-
Abstract:
The present analysis was based on the iteration of the 2023 WHO Essential Medicines Model List(23rd list)and Essential Medicines Model List for Children(9th list).In a methodological fashion,the adjustment procedure of the basic drug list and the materials required to submit the application were sorted out.Subsequently,a comprehensive synthesis of predominant features characterizing the 2023 edition of the EML and EMLc are summarized(offered).Notably,this edition boasts the highest count of medicines ever included featuring extensive inclusion of innovative drugs to fill the gap,select medicines for children carefully,and the emphasizing on clinical benefit evidence and public health affordability.It is suggested that China should update the NEML according to the national conditions and the experience of WHO as soon as possible,pay attention to the difference and connection between the list of essential medicines and the list of medical insurance,and play a meticulous role for establishing effective linkages between two lists.Such measures are envisaged to meet the basic drug needs,and ensure the accessibility and affordability of drugs,thereby optimizing the allocation of health resources.
